Steve Chatters

Steve Chatters joined OGT in September 2015, firstly as Product Manager for the CytoCell^® FISH probe range, then leading the Medical Affairs team in which he oversaw the successful FDA de novo 510(k) clearance of OGT CytoCell AML/MDS probes.

Steve was appointed Executive Vice President of Regulatory, Medical and Quality Affairs in July 2020 with responsibility for delivering OGT’s quality systems, regulatory processes and analytical testing.

Before joining OGT, Steve was Principal Clinical Scientist of the oncology cytogenetic service at Great Ormond Street Hospital in London UK and has over 20 years’ experience in specialist cancer diagnostic laboratories.